Reata Prescription drugs, Inc. Declares Closing of Class A Widespread Inventory Providing

PLANO, Texas, Dec. 04, 2020 (GLOBE NEWSWIRE) — Reata Prescription drugs, Inc. (Nasdaq: RETA) (“Reata” or the “Firm”), a clinical-stage biopharmaceutical firm, at this time introduced the closing of its beforehand introduced underwritten public providing of two,000,000 shares by the Firm of its Class A typical inventory, at a value to the general public of $140.85 per share, for gross proceeds of $281.7 million. Reata has granted the underwriters a 30-day choice to buy 300,000 further shares of its Class A typical inventory, on the identical phrases and situations because the shares provided within the public providing.

Barclays Capital Inc. and Goldman Sachs & Co. LLC acted because the joint book-running managers for the providing.

The securities described above have been provided pursuant to an mechanically efficient shelf registration assertion on Kind S-3. The providing was performed solely via a written prospectus and prospectus complement that kind part of the registration assertion. A closing prospectus complement and accompanying prospectus regarding the providing have been filed with the Securities and Change Fee (the “SEC”) and can be found on the SEC’s web site at www.sec.gov. Copies of the ultimate prospectus complement and the accompanying prospectus can also be obtained by request at Barclays Capital Inc., Consideration: Broadridge Monetary Options, 1155 Lengthy Island Avenue, Edgewood, New York 11717, phone: 1-888-603-5847, or by emailing Barclaysprospectus@broadridge.com; or Goldman Sachs & Co. LLC, Prospectus Division, 200 West Avenue, New York, NY 10282, phone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.e-mail.gs.com.

This information launch is for informational functions solely and shall not represent a suggestion to promote or the solicitation of a suggestion to purchase, nor shall there be any sale of those securities, in any state or jurisdiction through which such supply, solicitation or sale of those securities can be illegal previous to registration or qualification below the securities legal guidelines of any such state or jurisdiction.

About Reata Prescription drugs, Inc.

Reata is a clinical-stage biopharmaceutical firm that develops novel therapeutics for sufferers with severe or life-threatening ailments by concentrating on molecular pathways concerned within the regulation of mobile metabolism and irritation. Reata’s two most superior medical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, goal the vital transcription issue Nrf2 that promotes restoration of mitochondrial operate, discount of oxidative stress, and inhibition of pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational medication, and their security and efficacy haven’t been established by any company.

Ahead-Trying Statements

This press release contains sure disclosures that include “forward-looking statements,” together with, with out limitation, statements relating to the public providing and the anticipated use of web proceeds of the providing, the success, value and timing of our product improvement actions and medical trials, our plans to analysis, develop and commercialize our product candidates, our plans to submit regulatory filings, and our skill to acquire and retain regulatory approval of our product candidates. You’ll be able to determine forward-looking statements as a result of they include phrases resembling “believes,” “will,” “could,” “goals,” “plans,” “mannequin,” and “expects.” Ahead-looking statements are primarily based on Reata’s present expectations and assumptions. As a result of forward-looking statements relate to the long run, they’re topic to inherent uncertainties, dangers, and adjustments in circumstances which will differ materially from these contemplated by the forward-looking statements, that are neither statements of historic reality nor ensures or assurances of future efficiency. Necessary components that would trigger precise outcomes to vary materially from these within the forward-looking statements embody, however usually are not restricted to, (i) the uncertainties associated to market situations and the completion of the general public providing on the anticipated phrases or in any respect; (ii) the timing, prices, conduct, and consequence of our clinical trials and future preclinical research and medical trials, together with the timing of the initiation and availability of knowledge from such trials; (iii) the timing and probability of regulatory filings and approvals for our product candidates; (iv) whether or not regulatory authorities decide that further trials or information are needed as a way to receive approval; (v) the potential market measurement and the dimensions of the affected person populations for our product candidates, if authorized for business use, and the market alternatives for our product candidates; and (vi) different components set forth in Reata’s filings with the U.S. Securities and Change Fee, together with its Annual Report on Kind 10-Okay for the 12 months ended December 31, 2019 and Quarterly Report on Kind 10–Q for the quarter ended March 31, 2020, below the caption “Threat Components.” The forward-looking statements converse solely as of the date made and, aside from as required by regulation, we undertake no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new info, future occasions, or in any other case.

Contact:
Reata Prescription drugs, Inc.
(972) 865-2219

Investor Relations:
Vinny Jindal
(469) 374-8721
ir@reatapharma.com